Furthermore, EGFR mutations are rare (<1%) in colorectal cancer [18] and had no influence on anti-EGFR response in mCRC and therefore cannot be used to predict the clinical response to anti-EGFR monoclonal antibodies. The gene discussed is EGFR; the disease is colorectal cancer.